Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.
This is an unprecedented time in biomolecular medicine. Recent scientific findings have determined biofluids consist of circulating cell-free (cf)DNA and extracellular (ex)RNA from multiple tissues within the body. In addition, the rapid development of highly sensitive and accurate next-generation sequencing (NGS) technologies has empowered researchers to analyze the role of these biomolecules in health, disease and treatment response. However, there remains considerable insecurity associated with biofluid-based DNA/RNA analytical methods which must be solved before liquid biopsies can be implemented for broader routine applications.
Symposium June 22
Dinner Short Course June 23
Conference Sessions June 22 – 24
- Oncology: Liquid Biopsies Are Advancing into the Clinic
- Tools that Capture, Amplify and Analyze Minute Amounts of Nucleic Acids
- Moving Beyond Cancer: Tackling Other Targets
- Detecting the Role of Extracellular RNAs in Health and Disease